| Field | Specification |
|---|---|
| Target | |
| Alternative names | Annexin A4;35-beta calcimedin;Annexin IV;Annexin-4;Carbohydrate-binding protein p33/p41;Chromobindin-4;Endonexin I;Lipocortin IV;P32.5;PP4-X;Placental anticoagulant protein II;PAP-II;Protein II;ANXA4;ANX4; |
| UniProt # | |
| Host | |
| Clonality | |
| Isotype | |
| Reactivity | |
| Applications | |
| Immunogen | A synthetic peptide corresponding to a sequence in the middle region of human Annexin IV, different from the related mouse and rat sequences by three amino acids. |
| Molecular weight | |
| Purification | |
| Reconstitution | |
| Cellular localization | |
| Concentration | |
| Form | Lyophilized |
| Storage | |
| Catalog no. (Mfr.) | |
| Main SKU |
Product Overview
This rabbit polyclonal antibody recognizes annexin A4 (gene ANXA4) in human, mouse and rat samples and is validated for flow cytometry, IHC and Western blot. The predicted molecular weight is 35.9 kDa, and the supplier reports an observed band at about 36 kDa.
Annexin A4 (ANXA4) is a calcium- and phospholipid-binding protein that promotes membrane fusion and takes part in exocytosis. It is enriched in epithelial cells and is studied in membrane trafficking and ion transport.
| Target | Annexin A4 (gene ANXA4; UniProt P09525, human) |
|---|---|
| Host / Clonality / Isotype | Rabbit / Polyclonal / Rabbit IgG |
| Reactivity | Human, Mouse, Rat |
| Form | Lyophilized |
| Formulation | Per vial: 4 mg trehalose; 0.9 mg NaCl; 0.2 mg Na2HPO4 |
| Calculated MW | 35.9 kDa |
| Observed MW | 36 kDa |
| Storage | As supplied: −20 °C for up to 12 months from receipt. After reconstitution: 4 °C for up to 1 month, or aliquot and keep at −20 °C for up to 6 months. Avoid repeated freeze–thaw cycles. |
Validated Applications
| Western blot | 0.25–0.5 µg/mL (Human, Mouse, Rat) |
|---|---|
| IHC (paraffin sections) | 2–5 µg/mL (Human, Mouse, Rat) |
| Flow cytometry (fixed cells) | 1–3 µg/1×106 cells (Human) |
Samples with a confirmed band (WB): human HepG2 cells, human A549 cells, human THP-1 cells, human Hacat cells, rat stomach tissue, rat lung tissue, mouse stomach tissue, mouse lung tissue.
Recommended loading (WB): 20–40 µg of total protein per lane.
Conditions in the example images (WB): 5–20% gradient SDS-PAGE under reducing conditions, 30 µg lysate per lane, transfer to nitrocellulose membrane, blocking in 5% non-fat milk, primary antibody at 0.5 µg/mL overnight at 4 °C, HRP-conjugated secondary antibody at 1:5000, ECL detection.
Samples with confirmed staining (IHC): human breast cancer tissue, human colonic adenom tissue, human liver cancer tissue, human placenta tissue, mouse kidney tissue, rat kidney tissue.
Recommended antigen retrieval: heat-mediated, in TE buffer (pH 9.0); citrate buffer (pH 6.0) can be used instead.
Conditions in the example images (IHC): heat-mediated antigen retrieval in EDTA buffer (pH 8.0).
Samples with a confirmed signal (flow cytometry): HEL cells.
Immunogen
Synthetic peptide from the middle region of human annexin IV. It differs from the mouse and rat sequences at three residues.
Reactivity Notes
The supplier lists reactivity with human, mouse and rat. UniProt places annexin A4 in the zymogen granule membrane. The samples tested by the supplier (listed above) are a practical starting point for positive controls.
Safety
Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.
